Discrepancies Between Nomenclature and Indications of Psychotropics

Fusaka Minami, Joseph Zohar, Takefumi Suzuki, Teruki Koizumi, Masaru Mimura, Gohei Yagi, Hiroyuki Uchida

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction While the current nomenclature of psychotropic drugs is disease-based, their approved indications do not always match their classifications. Methods Information on approved indications of “second-generation antipsychotics” and “newer antidepressants” that are available in the United States (US), the United Kingdom (UK), France, Germany, and Japan were extracted from their packet inserts. Results A significant proportion of “atypical antipsychotics” were approved for psychiatric conditions other than psychotic disorders (i. e., bipolar disorder, major depressive disorder, and autistic disorder) as follows: 76.9% in the US, 66.7% in the UK, 66.7% in France, 60.0% in Germany, and 44.4% in Japan. Likewise, more than half of “newer antidepressants” had approved indications for psychiatric conditions other than depression (e. g., panic disorder, obsessive compulsive disorder, social anxiety disorder, general anxiety disorder, and post-traumatic stress disorder): 56.3% in the US, 69.2% in the UK, 69.2% in France, 50.0% in Germany, and 62.5% in Japan. Conclusions Our results raise concerns regarding generic terminologies of “antipsychotics” and “antidepressants” since the conventional indication-based nomenclature does not fit well with the official indication.

Original languageEnglish
JournalPharmacopsychiatry
DOIs
Publication statusAccepted/In press - 2018 May 23

Keywords

  • antidepressant
  • antipsychotic
  • indication
  • NbN
  • neuroscience-based nomenclature

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Discrepancies Between Nomenclature and Indications of Psychotropics'. Together they form a unique fingerprint.

Cite this